Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F–FDG PET/CT in pediatric patients with neuroblastoma

摘要

Abstract Purpose To evaluate the prognostic value of metabolic parameters and bone marrow uptake (BMU) patterns on pretherapeutic 18-F-fluorodeoxyglucose (18F–FDG) positron emission tomography/computed tomography (PET/CT) in pediatric patients with neuroblastoma (NB). Patients and methods Forty-seven pediatric patients with newly diagnosed neuroblastoma who underwent 18F–FDG PET/CT were retrospectively reviewed. Clinicopathological factors and metabolic parameters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and bone marrow uptake patterns on PET/CT were compared to predict recurrence-free survival (RFS) and overall survival (OS) by univariate and multivariate analysis. Results During the follow-up period, 27 (57.4%) patients experienced recurrence. MTV ( P ?=?0.001), TLG ( P ?=?0.004) and BMU patterns ( P ?=?0.025) remained significant predictive factors for tumor recurrence, along with tumor size, histology, stage, lactate dehydrogenase (LDH) and other distant metastasis (except bone metastasis). Univariate analysis showed that histology, stage, tumor size (>37.25?cm), other distant metastasis, MTV (>88.10cm 3 ) and TLG (>1045.2?g) and BMU patterns correlated with both RFS and OS ( P? ?0.05). On multivariate analysis, TLG remained the only independent prognostic factor for RFS ( P ?=?0.016) and OS ( P ?=?0.012), and BMU patterns and MTV were statistically significant for OS ( P ?=?0.024 and P ?=?0.038, respectively). Conclusion Pretherapeutic 18F-FDG PET/CT can provide reliable prognostic information for neuroblastoma pediatric patients, and patients with high MTV, TLG and focal bone marrow (unifocal and multifocal) uptake on PET/CT may have inferior outcomes during subsequent treatment.